Compare Quest Diagnostics Inc (DGX) vs FTAI Aviation Ltd (FTAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs FTAI Aviation Ltd — how do they compare? Quest Diagnostics Inc trades at $205.37 (market cap $22.80B), while FTAI Aviation Ltd trades at $212.8 (market cap $21.17B). The key difference: Quest Diagnostics Inc and FTAI Aviation Ltd are close in size by market cap, and Quest Diagnostics Inc pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| DGX | FTAI | |
|---|---|---|
Market Cap | $22.80B | $21.17B |
Sector | Health | Industrials |
52-Week High | $216.02 | $310.04 |
52-Week Low | $166.42 | $109.92 |
Enterprise Value | $28.82B | $24.21B |
Dividend Yield | 1.67% | 0.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
FTAI Aviation trades at $209.88, down 7.68% today, amid a bearish technical signal. The stock has missed earnings estimates for three consecutive quarters, though revenue and net income remain robust. Recent news highlights strategic collaborations and growth in data center power solutions. Analyst consensus is unanimously bullish with 18 buy ratings.
The outlook is supported by strong fundamentals and growth initiatives, but risks include earnings misses and high valuation multiples. The stock's near-term performance hinges on Q2 2026 results and execution of new business segments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →
